Chimeric Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHMMF research report →
Companywww.chimerictherapeutics.com
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric.
- CEO
- Rebecca McQualter
- IPO
- 2022
- HQ
- Carlton, VIC, AU
Price Chart
Valuation
- Market Cap
- $4.10M
- P/E
- -0.27
- P/S
- 1.44
- P/B
- -1.34
- EV/EBITDA
- -0.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.47%
- Op Margin
- -458.31%
- Net Margin
- -420.80%
- ROE
- 2844.96%
- ROIC
- 993.55%
Growth & Income
- Revenue
- $3.97M · 0.00%
- Net Income
- $-10,430,424 · 16.76%
- EPS
- $-0.77 · 57.22%
- Op Income
- $-15,111,460
- FCF YoY
- 3.48%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- 0.86
- Avg Volume
- 3.01K
Get TickerSpark's AI analysis on CHMMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CHMMF Coverage
We haven't published any research on CHMMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHMMF Report →